Ranbaxy pares losses in Q2; sticks to valsartan 'plan A'
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories reported a net loss of INR5.24bn ($85.5m) in the second quarter ended June impacted by forex losses and an impairment of goodwill in its French operations, although this was lower that the loss of INR5.86bn in the corresponding period of the previous year.